IP Library › Granted Patent US 12,409,167
Granted Patent B2
US 12,409,167 · App. 18/315,954 · Granted Sep 9, 2025

Pharmaceutical combination comprising a selective S1P

Inventors: Martine Clozel (Allschwil, CH); Luca Piali (Basel, CH)
Assignee: Vanda Pharmaceuticals Inc.
A61K31/426A61K9/0053A61K31/22A61K31/225A61K31/27A61K31/4015
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,409,167
App. No.
18/315,954
Granted
Sep 9, 2025
Kind
B2
Abstract

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E)but-2-ene-1,4-dioate, or a pharmaceutically acceptable salt thereof.

Claims (8)

1. A pharmaceutical combination comprising a first active ingredient which is about 10 mg of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-O-tolyl-thiazolidin-4 one or a pharmaceutically acceptable salt thereof and a second active ingredient which is dimethyl fumarate or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical combination according to claim 1 , wherein the first and the second active ingredient are comprised in a single pharmaceutical composition.

3. A pharmaceutical combination according to claim 1 , wherein the first and the second active ingredient are comprised in separated pharmaceutical compositions.

4. A medicament comprising the pharmaceutical combination according to claim 1 .

5. A pharmaceutical combination comprising a first active ingredient which is about 20 mg of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-O-tolyl-thiazolidin-4 one or a pharmaceutically acceptable salt thereof and a second active ingredient which is dimethyl fumarate or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical combination according to claim 5 , wherein the first and the second active ingredient are comprised in a single pharmaceutical composition.

7. A pharmaceutical combination according to claim 5 , wherein the first and the second active ingredient are comprised in separated pharmaceutical compositions.

8. A medicament comprising the pharmaceutical combination according to claim 5 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2024
From: ACTELION PHARMACEUTICALS LTD
To: VANDA PHARMACEUTICALS INC.
Reel/Frame 066276/0577 →
Priority Claims (1)
WO PCT/EP2014/077469 · Dec 11, 2014 · international
Continuity (4)
Continuation 17325912 · May 20, 2021
Continuation 16277829 · Feb 15, 2019
Division 15534951
Related Publication 20240139160A1 · May 2, 2024
References Cited (188)
US 4959389A · Speiser et al. · 1990 [cited by applicant]
US 7435828B2 · Binkert et al. · 2008 [cited by applicant]
US 7626037B2 · Binkert et al. · 2009 [cited by applicant]
US 7875726B2 · Binkert et al. · 2011 [cited by applicant]
US 7879821B2 · Hauser · 2011 [cited by applicant]
US 8263780B2 · Abele et al. · 2012 [cited by applicant]
US 8273779B2 · Binkert et al. · 2012 [cited by applicant]
US RE43728E · Binkert et al. · 2012 [cited by applicant]
US RE43833E · Binkert et al. · 2012 [cited by applicant]
US 8399514B2 · Lukashev et al. · 2013 [cited by applicant]
US 8492441B2 · Legangneux · 2013 [cited by applicant]
US 8524752B2 · Binkert et al. · 2013 [cited by applicant]
US 8669281B1 · Zeidan et al. · 2014 [cited by applicant]
US 8785484B2 · Brossard et al. · 2014 [cited by applicant]
US RE45174E · Binkert et al. · 2014 [cited by applicant]
US 8912340B2 · Abele et al. · 2014 [cited by applicant]
US 9000018B2 · Binkert et al. · 2015 [cited by applicant]
US 9062014B2 · Bonham et al. · 2015 [cited by applicant]
US 9340518B2 · Herse · 2016 [cited by applicant]
US 10220023B2 · Dingemanse et al. · 2019 [cited by applicant]
US 10245253B2 · Clozel · 2019 [cited by examiner]
US 11026927B2 · Clozel · 2021 [cited by examiner]
US 11672783B2 · Clozel · 2023 [cited by examiner]
US 20090182047A1 · Joshi et al. · 2009 [cited by applicant]
US 20100048651A1 · Gangakhedkar et al. · 2010 [cited by applicant]
US 20100160259A1 · Schmouder · 2010 [cited by applicant]
US 20100160369A1 · Canne Bannen · 2010 [cited by applicant]
US 20100260755A1 · Gammans et al. · 2010 [cited by applicant]
US 20110112196A1 · Lukashev · 2011 [cited by applicant]
US 20110200557A1 · Grima et al. · 2011 [cited by applicant]
US 20110274657A1 · Aguilar et al. · 2011 [cited by applicant]
US 20110311485A1 · Giulio et al. · 2011 [cited by applicant]
US 20120034303A1 · Nilsson et al. · 2012 [cited by applicant]
US 20120238028A1 · Reszka et al. · 2012 [cited by applicant]
US 20130259856A1 · Kaye et al. · 2013 [cited by applicant]
US 20130314669A1 · Levin et al. · 2013 [cited by applicant]
US 20130316003A1 · Nilsson et al. · 2013 [cited by applicant]
US 20140056973A1 · Ma et al. · 2014 [cited by applicant]
US 20140057917A1 · Cundy et al. · 2014 [cited by applicant]
US 20140099364A2 · Nilsson · 2014 [cited by examiner]
US 20140163100A1 · Dawson et al. · 2014 [cited by applicant]
US 20140179778A1 · Mao et al. · 2014 [cited by applicant]
US 20140303217A1 · Brossard et al. · 2014 [cited by applicant]
US 20140315964A1 · Brossard et al. · 2014 [cited by applicant]
US 20140316140A1 · Brossard et al. · 2014 [cited by applicant]
US 20150183741A1 · Guckian et al. · 2015 [cited by applicant]
US 20150203493A1 · Guckian et al. · 2015 [cited by applicant]
US 20150220693A1 · Cadavid et al. · 2015 [cited by applicant]
US 20150238602A1 · Cadavid et al. · 2015 [cited by applicant]
US 20150265580A1 · Brossard et al. · 2015 [cited by applicant]
US 20190091190A1 · Terwey et al. · 2019 [cited by applicant]
AU 0752733B2 · 2002 [cited by applicant]
AU 2013329421A1 · 2015 [cited by applicant]
CA 2834455A1 · 2012 [cited by applicant]
DE 102009008851A1 · 2010 [cited by applicant]
DE 102010048788A1 · 2011 [cited by applicant]
DE 102010026879A1 · 2011 [cited by applicant]
EP 0312697A2 · 1989 [cited by applicant]
EP 2137537A2 · 2009 [cited by applicant]
EP 2177521A1 · 2010 [cited by applicant]
EP 2202232A1 · 2010 [cited by applicant]
EP 2210890A1 · 2010 [cited by applicant]
EP 2305660A1 · 2011 [cited by applicant]
EP 2316430A1 · 2011 [cited by applicant]
EP 2343287A1 · 2011 [cited by applicant]
EP 2366702A1 · 2011 [cited by applicant]
EP 2390252A1 · 2011 [cited by applicant]
EP 2455080A1 · 2012 [cited by applicant]
EP 2692344A1 · 2014 [cited by applicant]
JP 2005535679 · 2005 [cited by applicant]
JP 2012500285A · 2012 [cited by applicant]
JP 2014515373A · 2014 [cited by applicant]
KR 102427123B1 · 2022 [cited by applicant]
WO 0030622A2 · 2000 [cited by applicant]
WO 2004010987 · 2004 [cited by applicant]
WO 2005005421A1 · 2005 [cited by applicant]
WO 2005054215A1 · 2005 [cited by applicant]
WO 2005082841A1 · 2005 [cited by applicant]
WO 2006058316 · 2006 [cited by applicant]
WO 2008062376A2 · 2008 [cited by applicant]
WO 2008097596A2 · 2008 [cited by applicant]
WO 2009115954A1 · 2009 [cited by applicant]
WO 2010022177A2 · 2010 [cited by applicant]
WO WO2010046835A1 · 2010 [cited by examiner]
WO 2010079222A1 · 2010 [cited by applicant]
WO 2011035900A1 · 2011 [cited by applicant]
WO 2011067243A1 · 2011 [cited by applicant]
WO 2011069647A1 · 2011 [cited by applicant]
WO 2011113578A1 · 2011 [cited by applicant]
WO 2011144338A1 · 2011 [cited by applicant]
WO 2012162669A1 · 2012 [cited by applicant]
WO 2012164026A1 · 2012 [cited by applicant]
WO 2013119677A1 · 2013 [cited by applicant]
WO 2013148690A1 · 2013 [cited by applicant]
WO 2014018891A1 · 2014 [cited by applicant]
WO 2014020156A1 · 2014 [cited by applicant]
WO 2014027330A1 · 2014 [cited by applicant]
WO 2014028299A1 · 2014 [cited by applicant]
WO 2014031844A1 · 2014 [cited by applicant]
WO 2014031892A1 · 2014 [cited by applicant]
WO 2014058875A2 · 2014 [cited by applicant]
WO 2014071371A1 · 2014 [cited by applicant]
WO 2014152494A1 · 2014 [cited by applicant]
WO 2015066515A1 · 2015 [cited by applicant]
WO 2016091996A1 · 2016 [cited by applicant]
WO 2016092042A1 · 2016 [cited by applicant]
Curtin et al., Novel therapeutic options for multiple sclerosis, Exert Rev. Clin. Pharmacol., 7(1), 91-104 (2014). [cited by examiner]
Brennan et al. Dimethyl Fumarate and Monomethyl Fumarate are Distinguished by Non-Overlapping Pharmacodynamic Effects In Vivo (P1.206), Neurology, Apr. 8, 2014; 82 (10 Supplement). [cited by examiner]
“Abstracts—ACTRIMS Forum 2017”, Multiple Sclerosis Journal, vol. 23, p. 2-90, (2017). [cited by applicant]
Brennan et al., “Dimethyl Fumarate and Monomethyl Fumarate are Distinguished by Non-Overlapping Pharmacodynamic Effects In Vivo (P1.206)”, Neurology, 2014, vol. 82, Suppl. 10. [cited by applicant]
Brossard et al., “Pharmacokinetics and Pharmacodynamics Of Ponesimod, A Selective S1P1 Receptor Modulator, In the first-in-human study”, British Journal of Clinical Pharmacology, 2013, vol. 76, No. 6, pp. 888-896. [cited by applicant]
Cohen et al., “The Future Of Multiple Sclerosis Treatment”, Journal of the Neurological Sciences, 2009, vol. 277, No. 51, pp. S55-S61. [cited by applicant]
Curtin et al., “Novel Therapeutic Options For Multiple Sclerosis”, Exert Rev. Clin. Pharmacol., 2014, vol. 7, No. 1, pp. 91-104. [cited by applicant]
Ellwardt et al., “Molecular Mechanisms Linking Neuroinflammation and Neurodegeneration in MS,” Experimental Neurology, 2014, vol. 262, pp. 8-17. [cited by applicant]
Fernandez et al., “Combination Therapy In Multiple Sclerosis”, Journal of the Neurological Sciences, 2007, vol. 259, pp. 95-103. [cited by applicant]
Fernandez et al., “Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III)”, Rev. Neurol., 2013, vol. 57, No. 7, pp. 317-329. [cited by applicant]
Olsson et al., “Oral Ponesimod In Relapsing-Remitting Multiple Sclerosis: A Randomised Phase II Trial”, Journal of Neurology, Neurosurgery and Psychiatry, 2014, vol. 85, pp. 1198-1208. [cited by applicant]
Pitarokoili et al., “Lewis Rat Model of Experimental Autoimmune Encephalomyelitis,” Current Protocols in Neuroscience, 2017, vol. 81, pp. 1-22. [cited by applicant]
Pouzol et al., “Complete Resolution Of Clinical Signs And Synergism Of The Combination Ponesimod-Dimethyl Fumarate In Rat Models Of Multiple Sclerosis”, Actelion Pharmaceuticals Ltd—Poster DMF-ponesimod ACTRIMS, 2017. [cited by applicant]
Remington, “The Science and Practice of Pharmacy”, 21st Ed., Part 5, Pharmaceutical Manufacturing, 2005. [cited by applicant]
Shin et al., “Mechanisms of Experimental Autoimmune Encephalomyelitis in Lewis Rats: Recent Insights from Macrophages,” Anat Cell Biol, 2012, vol. 45, pp. 141-148. [cited by applicant]
Shurin et al., “Immune-Mediated Diseases: Where Do We Stand?”, Part Of The Advances In Experimental Medicine And Biology Book Series AEMB, 2007, vol. 601, pp. 1-12. [cited by applicant]
Stahl et al., “Handbook of Pharmaceutical Salts, Properties, Selection and Use”, 2008, pp. 330-350. [cited by applicant]
Weaver et al., “An Elevated Matrix Metalloproteinase (MMP) In An Animal Model Of Multiple Sclerosis Is Protective By Affecting Th1/Th2 polarization”, The FASEB Journal, 2005, vol. 19, No. 12, pp. 1668-1670. [cited by applicant]
Wouters et al., “Pharmaceutical Salts and Co-crystals”, RSC Publishing, 2012. [cited by applicant]
Wustrow et al., “Comparison of the Efficacy and Tolerability of a Novel Methyl Hydrogenfumarate Prodrug with Dimethyl Fumarate in Rodent EAE and GI Irritation Models”, Neurology, 2011, vol. 76, No. 9, Suppl. 4, pp. A387. [cited by applicant]
“Actelion's Orally Active Selective S1P1 Receptor Agonist to be Jointly Developed/ Promoted with Roche in Autoimmune Disorders and Transplantation; Deal Potentially Worth well over US$630 Million to Actelion”, USCULO El… [cited by applicant]
Brinkmann, “Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology”, Pharmacology & Therapeutics, vol. 115, p. 84-105, (2007). [cited by applicant]
Brossard et al., “Effects on Heart Rate of Three Different Up-titration Regimens of Ponesimod, A Selective S1P1 Receptor Modulator, and of Re-Initiation of Treatment in Healthy Male and Female Subjects,” Multiple Sclero… [cited by applicant]
Brossard et al., “Effects of three different up-titration regimens of ponesimod, a selective S1P1 receptor agonist, on heart rate”, ECTRIMS Lyon France, p. 109, (2012). [cited by applicant]
Brossard et al., “Ascending multiple-dose study with ponesimod, a selective S1P1 receptor agonist: tolerability, safety, pharmacokinetics, and pharmacodynamics”, ECTRIMS Lyon France, p. 109, (2012). [cited by applicant]
Brossard et al., “Ascending single-dose study with ponesimod, a selective S1P1 receptor agonist: safety, pharmacokinetics, pharmacodynamics, and modeling”, ECTRIMS Lyon France, p. 111, (2012). [cited by applicant]
Brossard et al., “Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study”, British Journal of Clinical Pharmacology, vol. 76(6), p. 888-896, (2013). [cited by applicant]
Brossard et al., “A randomised, double-blind, ascending multiple-dose study with ponesimod, a selective S1P1 receptor modulator: safety, pharmacokinetics, pharmacodynamics”, ECTRIMS Lyon France, (2012). [cited by applicant]
Brossard P et al, “Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.”, Journal of Clinical Pharmacology Feb. 2014, (Feb. … [cited by applicant]
Brossard et al., “PII-109; Effects of Three Different Up-Titration Regimens of Ponesimod, a Selective S1p1 Receptor Agonist, on Heart Rate”, Nature, vol. 91, p. S92-S93, (2012). [cited by applicant]
Brossard et al., “PII-111; Ascending Single-Dose Study With Ponesimod, a Selective S1p1 Receptor Agonist: Safety, Pharmacokinetics, Pharmacodynamics, and Modeling”, Nature, vol. 91, p. S93, (2012). [cited by applicant]
Brossard et al., “ PII-110; Ascending Multiple-Dose Study With Ponesimod, A Selective S 1pl Receptor Agonist: Tolerability, Safety, Pharmacokinetics, And Pharmacodynamics”, Nature, vol. 91, p. S93, (2012). [cited by applicant]
Bunemann et al., “Activation of Muscarinic K+ Current in Guinea-Pig Atrial Myocytes by sphingosine-I-phosphate”, Journal of Physiology, vol. 489.3, p. 701-707, (1995). [cited by applicant]
Davidov et al., “Chronic nitric oxide synthase blockade desensitizes the heart to the negative metabolic effects of nitric oxide”, Life Sciences, vol. 79, p. 1674-1680, (2006). [cited by applicant]
Frolkis et al., “The Role of Invertors (Intracellular Activators) in Age-Related Changes in Cell Response to Hormones”, Experimental Gerontology, vol. 30(¾), p. 401-414, (1995). [cited by applicant]
Fujishiro et al., “Use of Sphingosine-I-Phosphate 1 Receptor Agonist, KRP-203, in Combination with a Subtherapeutic Dose of Cyclosporine A for Rat Renal Transplantation”, Transplantation, vol. 82(6), p. 804-812, (2006). [cited by applicant]
Guo et al., “Effects of Sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells”, European Journal of Physiology, vol. 438, p. 642-648, (1999). [cited by applicant]
Hale et al., “Selecting against S1P3 enhances the acute cardiovascular Tolerability of 3-(N-benzyl) aminopropylphosphonic acid S 1P receptor agonists”, Bioorganic & Medicinal Chemistry Letters, vol. 14, p. 3501-3505, (2… [cited by applicant]
Himmel et al., “Evidence for Edg-3 Receptor-Mediated Activation of IK.ACh by Sphingosine-I-Phosphate in Human Atrial Cardiomyocytes”, Molecular Pharmacology, vol. 58, p. 449-454, (2000). [cited by applicant]
Hoch et al., “Effect of Ponesimod, a Selective S1P1 Receptor Modulator, on the QT Interval in Healthy Individuals”, Basic & Clinical Pharmacology & Toxicology, vol. 116, p. 429-437, (2015). [cited by applicant]
Hoch et al., Oc015—Up-Titration Study With Ponesimod, a Selective S1p1 Receptor Modulator, to Assess Its Maximum Tolerated Dose in Healthy Subjects, Clinical Therapeutics, vol. 35(8S), p. e6-e7, (2013). [cited by applicant]
Hoch et al., “The Proceedings of the 12th Conference of the European Association for Clinical Pharmacology and Therapeutics”, Clinical Therapeutics, vol. XX(xx), (2015). [cited by applicant]
Hoch et al., “PP162—Thorough QT study with ponesimod, a selective S1P1 receptor modulator”, Clinical Therapeutics, vol. 35(8S), p. e68-e69, (2013). [cited by applicant]
Hoch et al., “A Novel Gradual Up-Titration Regimen Mitigates The First-Dose Effects Of Ponesimod, A Selective S1P1 Receptor Modulator”, Clinical Therapeutics, vol. 37 (8S), e36e37, (2015). [cited by applicant]
Hoch et al., “Clinical pharmacology of ponesimod, a selective S1P1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects”, European Journal of Pharmaceutical Sciences, vol. 63, p. 147-153, … [cited by applicant]
Huwiler et al., “New players on the center stage: Sphingosine 1-phosphate and its receptors as drug targets”, Biochemical Pharmacology, p. 1-8, (2008). [cited by applicant]
International Search Report of International Application No. PCT/EP2015/079208, dated Mar. 4, 2016, 4 pages. [cited by applicant]
Kappos et al., “Siponimod (BAF312) for the treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 Expand Trial”, Multiple Sclerosis and Related Disorders, vol. 3(6), p. 752, (2014). (http://dx.doi.… [cited by applicant]
Keller et al., “Immunomodulator FTY720 Induces Myofibroblast Differentiation via the Lysophospholid Receptor S1P3 and Smad3 Signaling”, The American Journal of Pathology, vol. 170, p. 281-292, (2007). [cited by applicant]
Kovarik et al., “A Mechanistic Study to Assess Whether Isoproterenol Can Reverse the Negative Chronotropic Effect of Fingolimod”, Pharmacodynamics, p. 1-8, (2008). [cited by applicant]
Koyrakh et al., “The Heart Rate Decrease Caused by Acute FTY720 Administration is Mediated by the G-Protein-Gated Potassium Channel IKACH”, American Journal of Transplantation, vol. 5, p. 529-536, (2005). [cited by applicant]
Krause et al., “Population modeling of the pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor agonist”, University of Auckland, New Zealand, p. 78, (2012). [cited by applicant]
Krause et al., “Population modeling of the pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor agonist”, Nature, vol. 91, p. S36-S37, (2012). [cited by applicant]
Krause et al., “Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator”, Journal of Pharmacokinetics Pharmacodynamics, vol. 41, p. 261-278, (2014). [cited by applicant]
Legangneux et al., “BAF312 Dose-Titration Scheme Significantly Attenuates Initial Heart Rate Reducing Effects in Healthy Subjects”, 63rd American Academy of Neurology Annual Meeting, Honolulu Hawaii, (2011). [cited by applicant]
Legangneux et al., “BAF312 Dose-Titration Scheme Significantly Attenuates Initial Heart Rate Reducing Effects in Healthy Subjects”, British Journal of Clinical Pharmacology, vol. 75(3), p. 831-841, (2012). [cited by applicant]
Ochi et al., “Sphingosine-I-phosphate Effects on Guinea Pig Atrial Myocytes: Alterations in Action Potentials and K+ Currents”, Cardiovascular Research, vol. 70, p. 88-96, (2006). [cited by applicant]
T. Olsson, Boster A., Fernandez O., Freedman M. S., Pozzilli C., Bach D., Berkani O., Mueller M. S., Sidorenko T., Radue E.-W., Melanson M., “Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase … [cited by applicant]
Peters et al., “Sphingosine-l-phosphate signaling in the cardiovascular system”, Current Opinion in Pharmacology, vol. 7, p. 1-7, (2007). [cited by applicant]
Rey et al., “Desensitization by Progressive Up-Titration Prevents First-Dose Effects on the Heart: Guinea Pig Study with Ponesimod, a Selective S1P1 Receptor Modulator”, PlosOne, vol. 8(9), p. e74285 (1-7), (2013). [cited by applicant]
Reyes et al., “Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive”, European Journal of Clinical Pharmacology, vol. 70, p. 287-293, (2014). [cited by applicant]
Sanna et al., “Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate”, The Journal of Biological Chemistry, vol. 279(4), p. 13839-13848, (2004). [cited by applicant]
Scherz Michael W., Brossard Patrick, D'ambrosio Daniele, Ipek Murat, Dingemanse Jasper, “Three different up-titration regimens of ponesimod, an S1P 1 receptor modulator, in healthy subjects : Journal of Clinical Pharmac… [cited by applicant]
Schmouder et al., “FTY720: Placebo-Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects”, Journal of Clinical Pharmacology, vol. 46, p. 895-904, (2006). [cited by applicant]
Vaclavkova et al., “Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial”, The Lancet, p. 1-10, (2014). [cited by applicant]
Wouters et al., “Pharmaceutical Salts and Cocrystals”, RSC Drug Discovery, p. 1-10, (2012). [cited by applicant]
Juif et al., “Mitigation of Initial Cardiodynamic Effects of the S1P1 Receptor Modulator Ponesimod Using a Novel Up-Titration Regimen”, The Journal of Clinical Pharmacology, vol. 57(3), p. 401-410, (2017). [cited by applicant]
Lott et al., “Tolerance modeling: effects of the selective S1P1 receptor modulator ponesimod on heart rate”, Universitat des Saarlandes—Population Approach Group Europe, 26th Meeting, Budapest 2017, p. 1, (2017). [cited by applicant]
Lott et al., “Modeling Tolerance Development for the Effect on Heart Rate of the Selective S 1Pi Receptor Modulator Ponesimod,” Clinical Pharmacology & Therapeutics, 10 pages (2017); DOI: 10.1002/cpt.877. [cited by applicant]
Piali et al., “The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation,” The Journal of Pharmacology and Experimental Therapeutics, vol. 337, No. 2, p.… [cited by applicant]
Basile Jan N., “Titration of beta-blockers in heart failure. How to maximize benefit while minimizing adverse events”, Postgraduate Medicine, (Mar. 1, 2003), vol. 113, No. 3, pp. 63-70, XP055980347. [cited by applicant]
De Vries et al., “Guide to Good Prescribing: A Practical Manual,” WHO Action Programme on Essential Drugs, 11 pages, (1994). [cited by applicant]
James p. Mc Cormack, G. Michael Allan Md, Adil S. Virani, “Is Bigger Better? An argument for very low starting doses”, CMAJ, (Jan. 11, 2011), vol. 183, No. 1, pp. 65-69, XP055913813. [cited by applicant]
International Search Report of International Application No. PCT/EP2015/079311, dated Feb. 25, 2016, 7 pages. [cited by applicant]
Brossard, vol. 54, Issue2 Feb. 2014 pp. 179-188 (Year: 2014). [cited by applicant]
Daniele D'Ambrosio, Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases, Therapeutic Advances in Chronic Disease vol. 7, Issue 1, Jan. 2016, pp… [cited by applicant]
De Vries T.P.G.M., Henning R.H., Hogerzeil H.V., Fresle D.A., “Annex 1—Essentials of pharmacology in daily practice”, Guide to Good Prescribing—A practical manual, (Jan. 1, 1998), pp. 98-104, XP055980341. [cited by applicant]
Notice of Allowance dated Sep. 30, 2024 for U.S. Appl. No. 18/046,492 (pp. 1-8). [cited by applicant]
Notice of Allowance dated Oct. 9, 2024 for U.S. Appl. No. 18/046,492 (pp. 1-6). [cited by applicant]
U.S. Appl. No. 17/325,912, filed May 20, 2021. [cited by applicant]
U.S. Appl. No. 16/277,829, filed Feb. 15, 2019. [cited by applicant]
U.S. Appl. No. 15/534,951, filed Jun. 9, 2017. [cited by applicant]